Case Study

Study Launches Early Phase In Australia With Later Expansion To China

Source: Novotech
GettyImages-91156547 clinical trial

Founded in 2017, a China-based biotech company was pursuing innovative treatments for oncology and immunology indications. Several years after launch, the biotech outsourced full-service CRO activities to Novotech for their Health Volunteer Immunology-focused Phase I study in 2020. The following year, the sponsor awarded Novotech full-service CRO activities for a second program with a different IP; a Phase Ib /II Advanced Solid Tumors combination study.

To extend its study into China, see how the sponsor facilitated clinical development plans for Phase II component, as quickly as possible.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader